ArticleCureus2025
Oral Ranitidine as an Immunomodulatory Agent in the Treatment of Molluscum Contagiosum: A Pediatric Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molluscum contagiosum (MC) is a common viral skin infection seen predominantly in children. While usually self-limiting, concerns over transmissibility and cosmesis often prompt active treatment. Traditional methods such as curettage, cryotherapy, and chemical agents may cause pain or scarring, limiting their use in young children. This case report highlights the successful treatment of MC with oral ranitidine, an H2-receptor antagonist known for its immunomodulatory properties. A six-year-old girl with multiple umbilicated papules on both buttocks achieved complete lesion clearance after eight weeks of oral ranitidine therapy at 5 mg/kg/day. No recurrence was observed over a six-month follow-up. Given its favorable safety profile and immunostimulatory potential, ranitidine may represent a viable, non-invasive therapeutic option for extensive or recurrent MC in immunocompetent pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.